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Abstract
Rationale
The sacred lotus (Nelumbo nucifera) contains many phytochemicals and has a history of
human use. To determine which compounds may be responsible for reported psychotropic
effects, we used in silico predictions of the identified phytochemicals. Nuciferine, an alkaloid
component of Nelumbo nucifera and Nymphaea caerulea, had a predicted molecular profile
similar to antipsychotic compounds. Our study characterizes nuciferine using in vitro and in
vivo pharmacological assays.
Methods
Nuciferine was first characterized in silico using the similarity ensemble approach, and was
followed by further characterization and validation using the Psychoactive Drug Screening
Program of the National Institute of Mental Health. Nuciferine was then tested in vivo in the
head-twitch response, pre-pulse inhibition, hyperlocomotor activity, and drug discrimination
paradigms.
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Results
Nuciferine shares a receptor profile similar to aripiprazole-like antipsychotic drugs. Nucifer-
ine was an antagonist at 5-HT2A, 5-HT2C, and 5-HT2B, an inverse agonist at 5-HT7, a partial
agonist at D2, D5 and 5-HT6, an agonist at 5-HT1A and D4 receptors, and inhibited the dopa-
mine transporter. In rodent models relevant to antipsychotic drug action, nuciferine blocked
head-twitch responses and discriminative stimulus effects of a 5-HT2A agonist, substituted
for clozapine discriminative stimulus, enhanced amphetamine induced locomotor activity,
inhibited phencyclidine (PCP)-induced locomotor activity, and rescued PCP-induced dis-
ruption of prepulse inhibition without induction of catalepsy.
Conclusions
The molecular profile of nuciferine was similar but not identical to that shared with several
approved antipsychotic drugs suggesting that nuciferine has atypical antipsychotic-like
actions.
1. Introduction
The lotus plants, Nelumbo nucifera andNymphaue caerulea, have been used by cultures, both
past and present, for their medicinal properties.[1] In eastern medicine, one of the cited potential
medical effects of the lotus is “calming emotional disturbance”.[2] The alkaloid nuciferine (Fig 1)
is thought to be responsible for the psychotropic effects ofNelumbo nucifera andNymphaea caer-
ulea, though its pharmacological properties are not entirely clear. Macko and colleagues [3]
observed that nuciferine produces effects similar to those of the antipsychotic chlorpromazine in
rodents. Bhattacharya and colleagues [4] observed that nuciferine produces antipsychotic-like
Fig 1. The chemical structure of nuciferine.
doi:10.1371/journal.pone.0150602.g001
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behavior in rats, including inhibition of the conditioned avoidance response and amphetamine-
induced behaviors. The behavioral effects previously observed in rodents, in addition to the cited
potential medical effects of the lotus in eastern medicine, led the authors to hypothesize that
nuciferine has a pharmacological profile similar to that of antipsychotic medications.
Most antipsychotics share common G protein-coupled receptor (GPCR) targets including
the D2 dopamine and 5-HT2A serotonin receptors. [5–7] Beyond these shared targets, antipsy-
chotic compounds exhibit diverse receptor affinity profiles. For example, the atypical antipsy-
chotic clozapine binds with nanomolar affinities to nearly 50 targets (Fig 2). [8] This
polypharmacological profile has been suggested as a path forward in therapeutic drug develop-
ment.[6, 9] Patterns of pharmacological activity responsible for antipsychotic efficacy remain
the subject of ongoing investigations. This polypharmacology approach presents a conundrum
for drug discovery efforts as it is impossible to design a compound for a polypharmacological
“target” (a pattern of molecular activity that engenders therapeutic efficacy) that has not yet
been elucidated. We therefore used ethnobotanical records of Nelumbo nucifera and Nymphaea
caeruleamedicinal properties as suggestive evidence for potential therapeutic efficacy of a
novel polypharmacological profile. Our in silico predictions of all phytochemicals identified in
Nelumbo nucifera suggest that nuciferine (and its metabolites) cross the blood-brain barrier
and have multiple protein targets. Furthermore, nuciferine has been shown to cross the blood
brain barrier in rats.[10] These predictions and previously reported data suggest that nuciferine
has a rich polypharmacology that is responsible for its psychotropic effects. We therefore inves-
tigated the in vitro and in vivo properties of nuciferine using cell-based pharmacology assays
and animal behavioral models of antipsychotic drug action.
2. Materials and Methods
2.1 Drugs
Nuciferine was purchased from Sequoia Research Products (Pangbourne, United Kingdom)
and Angene (Hong Kong, China) and was dissolved in DMSO at 10 mM for in vitro studies or
in 0.9% saline with 1 drop 85% lactic acid per 50 ml for animal studies. D-amphetamine
(AMPH), phencyclidine (PCP), and 2,5-dimethoxy-4-iodoamphetamine (DOI) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) and were dissolved in 0.9% saline. Clozapine
(Sigma-Aldrich) was dissolved in 0.2% acetic acid—2% cyclodextran solution. For animal stud-
ies, all drugs were administered intraperitoneally unless otherwise noted.
2.2 Bioinformatics
The profile of phytochemicals in Nelumbo nucifera was obtained fromMukherjee et al.[11]
The similarity ensemble approach (SEA) was utilized to predict molecular targets for each phy-
tochemical, using Scitegic ECFP4 fingerprints on a target panel extracted from a “binding” sub-
set of ChEMBL-12 [12] and standardized as previously described. [13, 14] Briefly, The SEA
[13–15] uses the chemical similarity of a bait molecule, against that of a set of ligands annotated
to a target, to predict whether the bait molecule will modulate that target. Briefly, SEA calcu-
lates the similarity of the bait molecule to every annotated ligand, typically using topological
fingerprints such as ECFP4. Similarity is calculated as the Tanimoto coefficient (Tc), the num-
ber of feature (bits) in common between the bait molecule and any given ligand, divided by the
total number of features (bits) in the two molecules; identical molecules will have Tc values of
1.0. The Tc values above a threshold value against all the ligands for the target are averaged,
and that Tc is compared to that expected for a set of ligands of similar size that would be
expected at random. An E-value is calculated by calculating a Z-score for the observed average
Tc vs. the ligand set, then plotting this value against an extreme value distribution and using
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Fig 2. Comparison of the polypharmacology of nuciferine with atypical and typical antipsychotics.
The empirical affinity values of three antipsychotics are shown (clozapine, haloperidol, aripiprazole). The
empirical nuciferine affinity profile from this study is shown in comparison. Values for clozapine, haloperidol,
and aripiprazole compiled from data available on the PDSP website accessed 20150428. Only “PDSP
verified” data was used for the figure. Data entries of “>10,000” were entered as 10,000 μM.
doi:10.1371/journal.pone.0150602.g002
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the BLAST sequence comparison machinery. This E-value represents the likelihood of seeing
the similarity one does, between the bait molecule and the known ligands for any given target,
compared to what one would expect at random. This calculation is repeated against all of
the> 2500 targets in ChEMBL [16] (https://www.ebi.ac.uk/chembl/). The blood-brain barrier
penetrability of each compound was predicted using the online blood-brain barrier prediction
(BBB) server [17] (http://www.cbligand.org/BBB/).
2.3 Psychoactive drug screening program affinity and functional profiling
The NIMH Psychoactive Drug Screening Program (PDSP) has published standardized meth-
ods for radioligand binding assays and functional assays. [9, 18–20] Full details of the methods
used in the radioligand receptor assays and the functional assays are described in the PDSP
Assay Protocol book (http://pdsp.med.unc.edu/pdspw/binding.php).
For affinity determination, nuciferine was subjected to primary radioligand binding assays
tested at a single 10 μM concentration to displace 50% of the radioligand at a given receptor
target. If a more than 50% of the radioligand was displaced, nuciferine was selected for a sec-
ondary binding assay tested at 11 concentrations in triplicate in competition with the radioli-
gand to generate an IC50 and Ki. Binding assays were performed in 96-well plates with 125 μL
per well in appropriate binding buffer using radioligand at or near the Kd. Plates are incubated
at room temperature in the dark for 90 min. Reactions are stopped by vacuum filtrations onto
0.3% polyethyleneimine soaked 96-well filter mats using a 96-well Filtermate harvester, fol-
lowed by at least three washes of cold wash buffer. Scintillation (MeltiLex) cocktail is melted
onto dried filters and radioactivity is counted using a Wallac Trilux Microbeta (Perkin Elmer).
For receptor functional assays, Gs or Gi-coupled receptor activation was measured using a
split-luciferase cAMP biosensor, GloSensor (Promega), and Gq-coupled receptor activation
was measured as calcium flux using Fluo-4 Direct Dye (Invitrogen). HEKT cells (ATCC) tran-
siently transfected or cells stably expressing the receptor were plated into 384-white (GloSen-
sor) or black plates (Calcium flux) in DMEM containing 1% dialyzed FBS at least 6 hours to 24
hours before the assay. For GloSensor, the media was decanted and replaced with 20 μL drug
buffer per well (HBSS, 20 mMHEPES, pH 7.4) containing GloSensor substrate. Cells were
challenged with 10 μL of nuciferine or positive control (3X) to generate 16 point concentration
curves and incubated for 15 minutes. For Gs-mediated cAMP accumulation, plates were read
immediately. For Gi-mediated cAMP inhibition, 10 μL of isoproterenol (200 nM final concen-
tration) was added to stimulate cAMP via endogenous β-adrenergic receptors and plates were
read 15 minutes later. Luminescence was measured using Wallac TriLux Microbeta (Perkin
Elmer) and luminescent counts per second (LCPS) was plotted. For Gq-mediated calcium flux,
media was decanted and replaced with 20 μL drug buffer containing 2.5 mM probenecid and
Fluo-4 dye and allowed to incubate for at least one hour at 37°C and 5% CO2 in a humidified
incubator. Afterwards, 10 μL of nuciferine or positive control (3X) was added per well for 16
point concentrations and fluorescence was measured using FLIPRTETRA (Molecular Devices).
Maximum-fold increase over basal fluorescence was plotted. Results were analyzed using non-
linear regression to obtain EC50 using Graphpad Prism 5.0.
2.4 Dynamic light scattering to test for colloidal aggregation
Nuciferine was diluted into filtered water from a 10 mM stock in DMSO with 50 mM potas-
sium phosphate, pH 7.0. Measurements were made at room temperature using a DynaPro MS/
X (Wyatt Technology) with a 55 mW laser at 826.6 nm. The laser power was 100%, and the
detector angle was 90° with samples run in duplicate.
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2.5 AmpC β-lactamase assay counterscreen to test for colloidal
aggregation
AmpC β -lactamase inhibition was measured in 50 mM potassium phosphate (pH 7.0) at room
temperature as described. [21] Nuciferine was diluted from a 10 mM stock in DMSO and incu-
bated with 1 nM AmpC for 5 minutes before the reaction was initiated by adding 92 μM
CENTA substrate (Tydock Pharma; Modena, Italy). The final reaction volume was 1 mL.
Change in absorbance was monitored at 405 nm for 2 minutes using an HP 8453 UV-Vis spec-
trophotometer. The assay was performed in duplicate in methacrylate cuvettes.
2.6 Vesicular monoamine transporter (VMAT2) study
Cell culture: HEK293 cells (ATCC) lines stably expressing hDAT or hDAT and hVMAT2 con-
structs were cultured at 37°C and 5% CO2 in DMEMwith 10% FBS. All constructs were made in
pcDNA3.1 (Life Technologies). hDAT and hVMAT2 expressing constructs contained a neomy-
cin or zeocin resistance gene, respectively. Plasmids were transfected into HEK293 cells with
Lipofectamine 2000. Stable cell lines were generated by repetitive rounds of limiting dilutions in
selective media. Double stable cell lines were created by transfecting HEK-hDAT stable cells with
the hVMAT2 construct and selecting for both plasmids with both neomycin and zeocin.
Whole cell 3H-dopamine (DA) uptake: Cells were plated into 48-well plates one day before
uptake was performed. Cells were washed with 0.5 ml uptake buffer (4 mM Tris, 6.25 mM
HEPES, 120 mMNaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 mMMgSO4, 5.6 mM D-glucose, 1.7
mM ascorbic acid, and 1 μM pargyline, pH 7.4). Cells were incubated with 225 μl uptake buffer
with or without the indicated concentration of nuciferine for 15 minutes. After incubation,
25 μl uptake buffer containing 3H-DA and DA was added for a final concentration of 20 nM
3H-DA and 1 μMDA. Cells were incubated at 37°C for 20 minutes or for the time indicated.
Nonspecific uptake was determined in the presence of 10 μM nomifensine. Uptake was termi-
nated by aspirating uptake buffer and washing each well twice with 0.5 ml ice-cold uptake
buffer. Cells were lysed in 0.1 N NaOH and transferred to vials containing 3 ml scintillation
cocktail. Radioactivity was quantitated using a Beckman LS6500 counter. Data were analyzed
in Graph Pad Prism 5.0.
Vesicular 3H-DA Uptake: Cells were plated in 10 cm dishes and grown to 100% confluency.
Cells were washed with warm PBS without Ca2+ or Mg2+and resuspended in uptake buffer (25
mMHEPES, 100 mM potassium tartrate, 100 μM EDTA, 50 μM EGTA, pH 7.4). Cells were
homogenized with a glass/Teflon homogenizer 30 times on ice. The homogenate was centri-
fuged at 8000xg for 8 minutes at 4°C. Protein content of the resulting supernatant was deter-
mined by BCA assay. Uptake assays utilized 100 μg of protein in complete uptake buffer
(uptake buffer with 1.7 mM ascorbate, 2 mMMg2+-ATP salt, pH 7.4) and 20 μM tetrabenazine
(TBZ) to define specific uptake. Samples were incubated in uptake buffer with or without the
indicated concentration of nuciferine for 10 minutes at 30°C followed by addition of 1 μM
dopamine with a 2% tracer of 3H-DA. Samples were incubated for 5 minutes at 30°C with gen-
tle shaking. The assay was terminated by addition of 5 ml ice-cold assay buffer before filtration
through 0.5% PEI-soaked Whatman GF/F filters (Brandel Inc., Gaithersburg, MD). Filters
were then placed in vials containing 3 ml scintillation fluid and counted using a Beckman
LS6500. Data were analyzed in Graph Pad Prism 5.0.
2.7 Animals
University of North Carolina at Chapel Hill: The head-twitch response, locomotor activity, and
catalepsy studies were run with male C57BL/6J mice bred at UNC. University of Arkansas for
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Medical Sciences: For DOI discrimination studies, adult male NIH Swiss mice weighing
approximately 25 g were obtained from Harlan Laboratories (Indianapolis, IN, USA) and
housed 3 mice per cage upon arrival. For PCP discrimination studies, adult male Sprague-Daw-
ley rats weighing approximately 250 g were obtained from Harlan Laboratories (Indianapolis,
IN, USA) and housed 3 rats per cage upon arrival. Virginia Commonwealth University: For
clozapine substitution studies, adult male 129S2/SvHsd inbred mice were bred in-house. Duke
University: adult male and female C57BL/6J mice, wild type (WT) mice, and dopamine trans-
porter knockout (DAT-KO) mice were used in PPI experiments. The DAT mice were gener-
ated by heterozygous matings. DAT mice were group-housed in an environmentally-
controlled room on a 14:10-h light/dark cycle (lights on 0800 h). The C57BL/6J, NIH Swiss,
and 129S2/SvHsd mice and the Sprague-Dawley rats were housed in environmentally-con-
trolled rooms on a 12:12-h light/dark cycle (lights on at 0700 hr). All experiments were con-
ducted with approved protocols from the Institutional Animal Care and Use Committees of
the university associated with each principal investigator: The University of North Carolina at
Chapel Hill Institutional Animal Care and Use Committee, the Duke University Institutional
Animal Care and Use Committee, the Virginia Commonwealth University Institutional Ani-
mal Care and Use Committee, and the University of Arkansas for Medical Sciences Animal
Care and Use Committee. It should be noted that the range of species and breeds used in these
studies was due to the “convenience and availability” nature of the collaboration, in which
nuciferine was tested in the established experimental protocols of the collaborating laboratories
dependent upon the availability of animals and openings in the experimental schedule.
2.8 Head-twitch responses
The head-twitch response procedure has been described elsewhere.[22–24] In brief, mice were
injected with either nuciferine (1.0, 3.0, or 10.0 mg/kg, i.p.) or vehicle, n = 4 mice/condition.
Fifteen minutes later, mice were injected with 1.0 mg/kg DOI (i.p.) and immediately placed in
an observation chamber (new cage without bedding). Head-twitches (operationally defined as
a rapid rotational jerk of the head that can be distinguished from species-appropriate grooming
or scratching behaviors) were counted for 20 minutes in 5 minute bins. For the time-course
study, mice were pretreated with 3.0 mg/kg nuciferine (i.p.) at 60, 45, 30, 15, or 0 minutes (co-
injection) prior to the 1.0 mg/kg DOI (i.p.) injection, and head-twitches were counted as
described above. In one experiment, mice (n = 4 per condition) were pretreated with an injec-
tion (s.c.) of 3.0 mg/kg nuciferine or vehicle 15 minutes prior to 1.0 mg/kg DOI injection (i.p.)
and head-twitches were counted as described above. All experiments were performed by 3
observers, with 2 observers blinded to the experimental conditions which were evenly distrib-
uted. Power analyses were performed with the resulting data. The two highest doses of nucifer-
ine tested (10.0 and 3.0 mg/kg), had 0.96 and 0.88 power to detect significance (α = 0.05). As
these experiments were performed blinded and in distinct mice, further replication was not
performed.
2.9 Open field activity
Locomotor activity was assessed in AccuScan activity monitors (41X41X30 cm; AccuScan
Instruments, Columbus, OH) with photocells spaced at 1.52 cm as described. [22] In these
monitors, the photocells create a grid of light beams, and breaks in the light beams (caused by
the mouse) are recorded. The Accuscan software then calculates the total distance travelled
(amongst other measurements) by analyzing the sequential order of beam breaks in the grid.
Horizontal activity was measured as the total distance traveled in centimeters and was recorded
in 5-minute bins. PCP-induced hyperlocomotor activity: mice (n = 16) previously acclimated
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to activity chambers were placed into the chambers for 15 minutes. Mice were then injected (i.
p.) with either vehicle or 3 or 10 mg/kg nuciferine and returned to the chamber for 15 min.
Subsequently, mice were injected with 6.0 mg/kg PCP (i.p.) and returned to the chamber for 90
minutes. Induction of AMPH-induced hyperlocomotor activity followed an identical protocol
except locomotor activity was recorded for a total of 75 minutes and 3 mg/kg AMPH was used
(i.p.).
2.10 Catalepsy procedure
Mice (n = 3) were initially injected (i.p.) with vehicle (0.9% saline/0.2% lactic acid), 10.0 mg/kg
nuciferine, or 1.0 mg/kg haloperidol. Mice were placed upright on a 45° angled screen. The
time required for the animal to move all four paws was scored in seconds (maximum of 5 min)
and is reported as the latency to movement. An extended delay to move on the inclined screen
test is indicative of drug-induced catalepsy. Power analyses were performed with the resulting
data. The experiment had 100% power to detect a significant difference (α = 0.05) between
nuciferine and haloperidol at the 60 minute timepoint.
2.11 DOI drug discrimination
Adult male NIH Swiss mice (n = 6) were trained to respond under an FR5 reinforcement
schedule by presentation of evaporated milk in daily sessions using procedures similar to those
previously described. [25] Mice were trained in drug discrimination via injection of saline
(VEH) or 0.3 mg/kg R(-)-DOI presented in a pseudo-random order, with the constraint that
no animal could receive the same injection for more than 3 consecutive sessions (1 session /
day). Response assignments were counterbalanced across trials. Drugs were administered i.p.
and pre-treatment time was 10 minutes. During each training session the overall response rate,
overall distribution of responses on the drug-injection lever, and the distribution of responses
on this same lever prior to delivery of the first reinforcer were analyzed. When animals reliably
achieved a level of>85% correct responding prior to delivery of the first reinforcer over 3 con-
secutive sessions, a substitution test occurred the following day. During test sessions, a multiple
component cumulative dosing procedure was used, and no responses were reinforced. Each
component was terminated after the emission of five responses on either lever. Mice were then
removed from the chamber, administered the next cumulative dose, and returned to the cham-
ber. Ten minutes later, levers were re-extended into the experimental chamber. In this manner,
four doses of drug could be tested over ~40 min in a single session. The distribution of
responses between the two levers was expressed as a percentage of total responses emitted on
the drug-appropriate lever. Response rate was calculated for each session by dividing the total
number of responses emitted on both levers by the elapsed time prior to 5 responses on either
lever. Nuciferine was administered 15 minutes prior to the first injection of DOI.
2.12 PCP drug discrimination
Adult male Sprague-Dawley rats (n = 5) were trained to respond under an FR20 schedule and
were reinforced by presentation of food pellets in daily sessions using procedures similar to
those previously described. [26] Rats were trained in drug discrimination via a pre-session
injection of saline (VEH) or 3 mg/kg PCP chosen in a pseudo-random order (coin flip), with
the same constraints, criteria, and dosing procedures as described above except that during test
sessions, a given component of the cumulative dosing procedure was terminated after the emis-
sion of 20 responses on either lever. Drugs were administered i.p. and pretreatment time was
10 minutes. As described above for DOI, four doses of drug could be tested in a single ~40 min
test session. Nuciferine was administered 15 minutes prior to the first injection of PCP.
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2.13 Clozapine drug discrimination study
Adult male B6129 hybrid mice (n = 12) were trained to respond under a FR10 schedule and were
reinforced by presentation of sweetened milk as described previously. [27] The drug and vehicle
lever positions were counterbalanced between groups to control for olfactory cues. [28] All injec-
tions were given subcutaneously with a pre-session injection time of 30 minutes. Training occurred
on a double alternation injection schedule with two days of VEH followed by two days of CLZ and
repeated (VEH, VEH, CLZ, CLZ, VEH, VEH etc.). In order for a mouse to pass a training day it
had to meet three criteria: (1) complete the first fixed ratio (FR) on the condition-appropriate lever,
(2) at least 80% of the total responses were made on the condition-appropriate lever, and (3) at
least 10 responses per minute were made during the session. Drug testing was conducted approxi-
mately two times per week with at least two training days in between. To be eligible for testing,
mice were required to pass both a drug and vehicle training day consecutively. During drug substi-
tution tests, animals were injected subcutaneously with nuciferine (0.1, 0.3, 1.0, 3.0, 10.0 mg/kg)
and placed in the operant chamber after 30 minutes. Responses on both levers were reinforced.
2.14 Prepulse inhibition (PPI)
PPI of the acoustic startle response was conducted as described elsewhere [29] using SR-LAB
chambers (San Diego Instruments, San Diego, CA). To determine whether nuciferine could
ameliorate or normalize PPI, two separate experiments were conducted. In the first, C57BL/6J
mice were administered VEH, 5, or 10 mg/kg nuciferine (i.p.) and returned to their home-
cages for 15 min. Subsequently mice were treated with either VEH or 6 mg/kg PCP (i.p.) and
placed into the PPI apparatus for a 5 min habituation prior to the onset of testing. In the sec-
ond study, WT and DAT-KO mice were given VEH or 2.5, 5, or 10 mg/kg nuciferine or 2 mg/
kg clozapine (i.p.) and returned to their home-cages. Fifteen min later DAT mice were habitu-
ated to the PPI apparatus for 5 min and testing began. The startle trials consisted of a 40 msec
burst of 120dB white-noise; prepulse trials consisted of 20 msec prepulse stimuli that were 4, 8,
or 12 dB above the white-noise background (64dB) and were followed 100 msec later by the
120dB acoustic startle stimulus. Non-stimulus or null trials consisted of the 64dB white-noise
background. PPI responses were calculated as a percentage score for each prepulse intensity,
where %PPI = [1–(prepulse trials/startle-only trials)]100.
2.15 Statistics
The data are presented as means and standard errors of the mean (SEM) and data from the
locomotor activity, head-twitch, and PPI studies were analyzed by SPSS statistical software
(IBM Corp., Armonk, NY). Locomotor data were assessed with repeated measures ANOVA
(RMANOVA) for within subject effects of time and for between subjects effects of treatment;
head-twitch data were similarly assessed with RMANOVA. ANOVA and independent mea-
sures t-test were used to also examine treatment differences in motor activity. For the PPI
experiment, the responses to the null and startle stimuli were analyzed by two-way ANOVA,
whereas the PPI data were subjected to RMANOVA where the within subjects effect was pre-
pulse intensity and the between subjects effects were treatment and, in the case of the DAT
mice, genotype. All post-hoc analyses were by Bonferroni corrected pair-wise comparisons. A
p<0.05 was considered significant. In the drug discrimination studies for each test session,
mean (±SEM) percent responding on the drug-associated lever and the rate of responding
(responses/sec) were calculated for each session component. Full substitution was operationally
defined as>80% selection of the drug-associated lever, partial substitution was operationally
defined as 40%-80% selection of the drug-associated lever, and no substitution was operation-
ally defined as<40% selection of the drug-associated lever. Subjects failing to complete the
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response requirement in a given component were excluded from the data analyses, but their
data were included in response rate calculations. Discrimination and response rate data were
not normally distributed, so the Kruskal-Wallis one-way ANOVA on ranks was used to ana-
lyze data across dose, comparing 3 treatment conditions: 1) training drug alone, 2) training
drug + 1.0 mg/kg nuciferine, and 3) training drug + 3.0 mg/kg nuciferine. Significant ANOVAs
were followed by pair-wise multiple procedures using the Dunn's method (α = 0.05) to deter-
mine differences among means.
3. Results
3.1 Prediction, in vitro identification, and in vitro characterization of
nuciferine
The in silico assessment of phytochemicals in Nelumbo nucifera (Fig 3) suggested that nucifer-
ine and its metabolites are the most structurally similar to known compounds (Fig 3; color of
circles). Additionally, nuciferine and its metabolites have high confidence protein-binding pre-
dictions (Fig 3; size of circles) and are predicted to cross the blood brain barrier (y axis). Finally,
nuciferine is predicted to have a relatively large number of molecular targets (x axis).
Next we compared the polypharmacological profile of nuciferine with two atypical antipsy-
chotic drugs (clozapine and aripiprazole) and the typical antipsychotic drug haloperidol (Fig
2).This convergence of predictions coupled with the potential utility of a compound with high
polypharmacology suggested that nuciferine (Fig 1) would be the most pharmacologically
interesting to investigate. Notable predictions from the SEA [13] are listed in Table 1, of which
we were capable of testing 10 via the National Institute of Mental Health Psychoactive Drug
Screening Program (PDSP).
The PDSP in vitro affinity screening (Tables 1 and 2) revealed a total of 13 receptors with
affinities less than 1 μM, and 21 receptors with affinities less than 10 μM. SEA successfully pre-
dicted 7 out of 13 G protein-coupled receptors that were determined by the PDSP to have Ki val-
ues of less than 1 μM. Functional studies (Table 1) indicate that nuciferine shows appreciable
potency as a D2 partial agonist (EC50 = 64 nM), as a 5-HT7 inverse agonist (EC50 = 150 nM), and
as a 5-HT2C antagonist (IC50 = 131 nM). [30] Nuciferine was a partial agonist at D2 receptors
with an activity (Emax = 67% of dopamine, Fig 4A) similar to aripiprazole (Emax = 50% of dopa-
mine).[19, 31] In line with its partial agonist activity, nuciferine inhibited dopamine-induced
activation of Gi (Fig 4B) with a potency similar to clozapine (nuciferine KB = 62 nM; clozapine
KB = 20 nM) as determined via Schild regression analysis. [32] Also similar to clozapine, nucifer-
ine exhibits 5-HT2A antagonist activity (IC50 = 478 nM) and 5-HT7 inverse agonist activity (IC50
= 150 nM), [33] and may effectively antagonize 5-HT6 receptors as a low efficacy partial agonist
(EC50 = 700 nM, 17.3%maximal effect). [2, 34] Finally, nuciferine exhibited micromolar potency
as a 5-HT2B antagonist (IC50 = 1 μM), a D4 agonist (EC50 = 2 μM), a D5 partial agonist (EC50 =
2.6 μM, 50%maximal response), and a 5-HT1A agonist (EC50 = 3.2 μM).
3.2 Assessment of aggregator properties
The predominantly low-potency antagonist activity of nuciferine suggested that nuciferine
could be functioning as a colloidal aggregator, a well-known mechanism of promiscuous activ-
ity in early discovery, such as high-throughput screening. [35, 36] Recent studies have shown
this mechanism can affect membrane-bound receptors such as GPCRs [37] in cell-based
screening. At concentrations relevant to this study (< = 10 μM), dynamic light scattering deter-
mined that nuciferine did not scatter light above background in aqueous buffer, suggesting col-
loidal aggregates of nuciferine are not formed at this concentration. Consistent with this,
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nuciferine did not inhibit AmpC β-lactamase at these concentrations; AmpC is a counter-
screening enzyme widely used to test for colloidal aggregation [35, 36, 38] (data not shown).
The lack of particle formation by light scattering and the lack of inhibition of the orthogonal
counter-screening enzyme supports the idea that nuciferine is not acting promiscuously via
colloidal aggregation in the assays described here.
3.3 Dopamine transport by DAT and VMAT2
SEA predicted that nuciferine may interact with the vesicular monoamine transporter-2
(VMAT2). To determine if nuciferine affects uptake at VMAT2, we conducted dopamine
Fig 3. Bioinformatic predictions of lotus phytochemicals. X axis = number of unique predicted targets, as
predicted by SEA. Each unique target included all affinity classes. Y axis = prediction of blood brain barrier
penetration using the online blood-brain barrier prediction (BBB) server [17] (http://www.cbligand.org/BBB/).
Higher values are predicted to pass the blood brain barrier. Size of circles = mean of -log10(e-value) for SEA-
predicted targets. Larger circles indicate stronger confidence of predicted targets. Color of circles = Mean of
max T values. Warmer colors (red) indicate better molecule-molecule matching, a second measure of
prediction confidence. Y axis reference line (0.0815) and X axis reference line (17) are the average value for
the world’s most widely prescribed psychiatric medications (aripiprazole and quetiapine).[74] These
predictions suggest that nuciferine and its metabolites (O-nornuciferine, lirinidine) may be responsible for the
psychotropic effects reported in humans. Chemical structures of nuciferine, O-nornuciferine, and lirinidine
provided.
doi:10.1371/journal.pone.0150602.g003
Characterization of Nuciferine
PLOS ONE | DOI:10.1371/journal.pone.0150602 March 10, 2016 11 / 27
uptake experiments in vesicles isolated from HEK cells overexpressing VMAT2 and found no
effect of nuciferine on DA uptake (Fig 5A). We also tested whether nuciferine affected uptake in
whole-cell uptake studies in HEK cells expressing DAT and VMAT2 or DAT alone as a control,
as described elsewhere. [39] In whole cells expressing DAT and VMAT2, the total capacity of the
cell to take up and store dopamine is measured. This has a DAT-mediated and a VMAT2-me-
diated component, as previously demonstrated.[39] Comparison of the effects of compounds in
these two cell types, as well as in isolated vesicles, aids in separating out these two components of
uptake in whole cells. Nuciferine pre-treatment had no effect in HEK-DAT/VMAT2 cells (Fig
5B). Counter to predictions, in the HEK-DAT control cells, nuciferine pre-treatment increased
uptake in HEK-DAT cells by 60% over the vehicle control (Fig 5C; EC50 = 1.8 nM).
3.4 DOI-induced head-twitch response (HTR)
Mice pretreated with nuciferine (1.0, 3.0 and 10.0 mg/kg, i.p. or 3 mg/kg, s.c.;15 min prior to
DOI) showed a dose-dependent inhibition of the head-twitch response produced by 1.0 mg/kg
DOI during the course of testing (Fig 6A). Bonferroni corrected pair-wise comparisons indi-
cated that regardless of route of injection, nuciferine attenuated DOI-induced head-twitches at
10, 15 and 20 min (ps<0.05). When the different doses of nuciferine were examined, a RMA-
NOVA revealed a significant effect of time [F[3,36] = 232.725, p<0.0001], and a significant time
by treatment interaction [F[9,36] = 16.170, p<0.0001]. Bonferroni comparison results indicated
that 3 and 10 mg/kg nuciferine decreased head-twitches at 5, 10, 15 and 20 min (ps<0.05) rela-
tive to DOI-treated mice. Differences in responses to the 3 and 10 mg/kg doses were not statis-
tically significant (Fig 6A). By comparison, 1 mg/kg nuciferine exerted no statistical effect on
the DOI induced head-twitches.
The time-course of 3 mg/kg nuciferine pre-treatment (i.p.) indicated that suppression of the
DOI-induced head-twitches was most pronounced when the interval between the nuciferine
Table 1. In silico and in vitro characterization of nuciferine.
SEA Predictions (in order of confidence) In Vitro Affinity (nM) Functional EC50 (nM) Function Type
Radioligand used
D1 (5.4e-32) 752 [
3H]SCH23390
D2 (1.6e-25) 515 [
3H]N-methyl Spiperone 65.07 Partial agonist
D3 (1.3e-12) 741 [
3H]N-methyl Spiperone
D5 (5.0e-13) (neg) [
3H]SCH23390 2600 Partial agonist, ~50%
VMAT2 (2.1e-13) NA
SK Channel (3.8e-11) NA
5-HT1A (1.2e-11) 77 [
3H]WAY100635 3230 Agonist
5-HT5B (1.6e-7)
5-HT7 (4.1e-4) 49.8 [
3H]LSD 150 Inverse agonist
5-HT2A (4.1e-6) 312 [
3H]Ketanserin 478 Antagonist
Unpredicted Hits
5-HT2B 41 [
3H]LSD 1000 Antagonist
5-HT2C 60.5 [
3H]Mesulergine 131 Antagonist
5-HT6 268 [
3H]LSD 700 Partial agonist, 17.3%
D4 1387 [
3H]N-methyl Spiperone 2000 agonist
Receptor targets are listed with their respective SEA prediction value (if available), followed by their competition binding affinity value (if available),
followed by their functional EC50 value (if available) and the corresponding function type.
Information about cell lines for all assays can be found at http://pdsp.med.unc.edu/pdspw/binding.php.
doi:10.1371/journal.pone.0150602.t001
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and DOI injections was 15 min (Fig 6B). When the interval between nuciferine and DOI injec-
tions was varied, a RMANOVA found the main effect of time [F[9,54] = 334.913, p<0.001] and
the time by pre-treatment interval [F[15,54] = 5.838, p<0.001] to be significant. Bonferroni anal-
yses indicated that mice treated 45 or 60 min prior to DOI injection failed to show significant
alterations in head-twitches compared to DOI-treated animals (Fig 6B). By contrast, mice
treated 15 or 30 min prior to the DOI injection all had statistically significant (p<0.05) reduc-
tions in the numbers of head-twitches compared to mice given DOI at the 5, 10, 15, and
20-min sampling times. Moreover, nuciferine pretreatment at 15 min produced the most pro-
found overall reductions in head-twitches relative to animals pretreated at 45 and 60 min and
measured at 15 and 20 min sampling times, all of which were statistically significant (p<0.05).
Collectively, these data demonstrate that nuciferine can antagonize DOI-induced head twitches
and that these effects are time-dependent with the 15 min interval between nuciferine and DOI
injection being the most effective.
3.5 Drug discrimination
Dose-dependent generalization for the DOI training dose was observed when cumulative doses
were administered alone, with cumulative doses of 0.1 and 0.3 mg/kg producing full substitu-
tion (Fig 7A). In the presence of 1.0 mg/kg nuciferine, however, cumulative DOI doses only
produced partial substitution, whereas in the presence of 3.0 mg/kg nuciferine, no cumulative
dose of DOI substituted for the training dose, up to a dose that profoundly suppressed
responding (Fig 7D). Although the overall ANOVA was significant (p<0.001), no within-dose
Table 2. In vitro affinity findings lacking functional measurements.
PDSP Hits Without Functional Assay In vitro Affinity (nM) Radioligand used
5-HT1D 518 [
3H]5-CT
α1A 1386 [
3H]Prazosin
α1B 1995.3 [
3H]Prazosin
α1D 818 [
3H]Prazosin
α2A 1153.5 [
3H]Rauwolscine
α2B 686.8 [
3H]Rauwolscine
α2C 692.8 [
3H]Rauwolscine
β1-AR 7149 [
3H]CGP12177
β3-AR 1103 [
3H]CGP12177
DOR 10000 [3H]DADLE
H2 1662 [
3H]Cimetidine
MOR 9549.00 [3H]DAMGO
V1A 10000 [3H]Vasopressin
5-HT5A 1113 [
3H]LSD
Receptor targets not predicted by SEA but identified by in vitro competition binding assays for which
functional assays are not available. The following receptors assayed in the PDSP screen had no observed
binding of nuciferine. Receptors are listed with their associated radioligand in (). Sets of receptors using the
same radioligand are indicated in []: [5-HT1B, 5-HT1E]([3H]5-CT), 5-HT3 ([3H]GR65630), β2-AR ([3H]
CGP12177), BZP Rat Brain Site ([3H]Flunitrazepam), D5([3H]SCH23390), DAT([3H]WIN35428), GabaA
([3H]Muscimol), H1 ([3H]Pyrilamine), H3 ([3H]α-methylhistamine), H4 ([3H]Histamine), KOR ([3H]U69593),
NMDA PCP site ([3H]MK801), [M1, M2, M3, M4, M5]([3H]QNB or [3H]NMS), NET ([3H]Nisoxetine), Oxytocin
([3H]Oxytocin), SERT ([3H]Citalopram), Sigma 1 ([3H]Pentazocine), Sigma 2 ([3H]DTG), [V1B, V2]([3H]
Vasopressin).
doi:10.1371/journal.pone.0150602.t002
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pairwise comparisons reached statistical significance. Dose-dependent generalization for the
PCP training dose was observed when cumulative doses were administered alone, with a cumu-
lative dose of 3.0 mg/kg producing full substitution. In the presence of 1.0 or 3.0 mg/kg nucifer-
ine, cumulative PCP doses produced similar substitution to PCP alone (Fig 7B). Although the
overall ANOVA was significant (p<0.05), no within-dose pairwise comparisons reached statis-
tical significance. In the clozapine-trained animals, a dose-dependent substitution for 1.25 mg/
kg clozapine was seen at 10.0 mg/kg nuciferine (80.63% drug lever responding), with an ED50
value of 5.42 mg/kg (95% CI 3.09–9.48 mg/kg) while the lower doses tested (0.1 mg/kg–3.0 mg/
kg) failed to produce substitution for clozapine’s discriminative cue (Fig 7C). In addition to a
Fig 4. Nuciferine functional activity at the dopamine D2 receptor as measured via D2-mediated Gi
signaling in HEKT cells. (a) Concentration-response curve of nuciferine (red) compared to dopamine
(black) and aripiprazole (blue). (b) Concentration-response curve of dopamine (DA) in the presence of 1 μM
nuciferine (red) or clozapine (green) showing rightward-shift of DA indicative of competitive antagonist
activity. The data represent concentration-response curves of normalized data with respect to dopamine
performed in triplicate (mean +/- s.e.m.; n = 3).
doi:10.1371/journal.pone.0150602.g004
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high percentage of responding on the clozapine-appropriate lever, 10.0 mg/kg nuciferine
also produced significant rate suppression as compared to vehicle control points (p< 0.001)
(Fig 7F).
3.6 Locomotor activity
Stimulation of locomotor activity by 6.0 mg/kg PCP was significantly blocked by 10.0 mg/kg,
but not by 3.0 mg/kg, nuciferine (Fig 8A. left panel). RMANOVA revealed a significant effect
of time [F[17,765] = 30.553, p<0.001], and a significant time by treatment interaction [F[34,765] =
1.997, p<0.010]. Bonferroni corrections indicated that during the 0–30 min interval locomo-
tion in all groups was similar. As expected, PCP stimulated locomotor activity from 35–90 min
compared to baseline at 0–30 min (ps<0.001). Treatment with 3 mg/kg nuciferine prior to
PCP failed to significantly alter the PCP-induced hyperlocomotion, whereas the 10 mg/kg
nuciferine significantly depressed this locomotion compared to PCP-treated mice at 45–60
min (p<0.05). Nevertheless, the reductions in PCP-stimulated activity by 3 and 10 mg/kg nuci-
ferine were not statistically different. When the results were presented as cumulative distance
traveled between 45 and 60 min of testing, dose-dependent decreases in PCP-stimulated activ-
ity could be seen (Fig 8A, right panel). ANOVA found a significant effect of treatment [F[2,47] =
4.323, p<0.05] and Bonferroni tests confirmed that 10 mg/kg nuciferine significantly reduced
locomotion compared to PCP (p<0.05). The 3 mg/kg dose decreased activity, but it was not
significantly different from the PCP alone or the 10 mg/kg plus PCP group.
A second set of mice was used to assess the effects of 3 mg/kg nuciferine pre-treatment on
amphetamine induced hyperlocomotion (Fig 8B, left panel). A RMANOVA revealed a signifi-
cant effect of time [F[13,390] = 177.243, p<0.001] and a significant time by treatment interaction
[F[13,390] = 14.625, p<0.001]. Bonferroni corrected comparisons found that activities between
the two group at 0–30 min were not statistically different. All animals showed a significant
increase in activity following amphetamine treatment compared to their baseline activities
(p<0.001). Those mice given nuciferine prior to amphetamine treatment showed significantly
higher motor activity between 35–50 min compared to those given amphetamine alone
(p<0.05); however, responses after this time were not significantly differentiated. When the
distance travelled in the open field for the 40 min following amphetamine treatment was aggre-
gated, mice given nuciferine followed by amphetamine had heightened activity compared to
those animals given amphetamine alone (Fig 8B, right panel) [t[1,30] = 4.014, p<0.001].
Fig 5. DATmodulation by nuciferine. (a) Concentration-response curves of nuciferine on vesicular uptake in isolated vesicles, (b) concentration-response
curves of nuciferine on vesicular uptake in HEK cells transfected with DAT and VMAT2, (c) concentration response curves of nuciferine on vesicular uptake
in HEK cells transfected with DAT. Data are presented as a percentage of the response to vehicle control. The data represent concentration-response curves
of normalized data with respect to vehicle performed in triplicate (mean +/- s.e.m.; n = 3).
doi:10.1371/journal.pone.0150602.g005
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Together, these findings indicate that while nuciferine is capable of attenuating the hyperloco-
motion induced by PCP, amphetamine induced hyperlocomotion is exacerbated by the
compound.
3.7 Pre-pulse inhibition
For the experiment with C57BL/6J mice a two-way ANOVA was applied with two levels of
treatment: PCP (vehicle or VEH and PCP) and nuciferine (VEH and the two doses of nucifer-
ine) constituted the 6 groups. A two-way ANOVA for null activity identified a main effect of
PCP treatment [F(1,45) = 31.70, p<0.001], but the nuciferine treatments and the PCP by nuci-
ferine interaction was not significant. Although Bonferroni corrected pair-wise comparisons
Fig 6. Inhibition of the 5-HT2A mediated, DOI-induced head-twitch response by nuciferine. (a) Dose
response curves of a 15-minute nuciferine pretreatment on the 1.0 mg/kg DOI-induced head twitch response.
Solid lines indicate intraperitoneal administration of nuciferine. Dashed line indicates subcutaneous
administration of nuciferine. Dose of nuciferine indicated to right of its associated data line. (b) Effect of
nuciferine pretreatment time on the suppression of the DOI-induced head-twitch response. All pretreatments
were administered intraperitoneally. DOI-alone condition provided as reference. Pretreatment time indicated
to right of its associated data line. Data are presented as the mean number of cumulative head-twitches (y
axis) at the given time point (x axis) (mean +/- s.e.m.; n = 3).
doi:10.1371/journal.pone.0150602.g006
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noted that null activity was higher in the PCP-treated groups than in the respective vehicle/
nuciferine groups (p<0.001), this activity was still less than 7% of the startle responses in the
PCP-treated group (Fig 9A). A two-way ANOVA for startle responses also observed a signifi-
cant main effect of nuciferine treatment [F(2,45) = 13.22, p<0.001]; the PCP treatment effect
and the PCP by nuciferine interaction was not significant. Bonferroni post-hoc tests reported
that startle responses for the 5 and 10 mg/kg nuciferine-treated groups were lower than those
of the vehicle-treated groups (p<0.001; Fig 9B). RMANOVA for PPI revealed the within sub-
jects main effects for prepulse intensity was significant [F(2,90) = 93.16, p<0.001]; the prepulse-
intensity by PCP treatment, prepulse-intensity by nuciferine treatment, and the prepulse-
intensity by PCP by nuciferine treatment interactions were not significant (Fig 9C). Bonferroni
tests demonstrated that the response to the 4dB prepulse was lower than that for the 8 and
12dB prepulse responses (p<0.001) and that the 8dB response was lower than that for the
12dB response (p<0.001). Regardless of prepulse intensity, the between subjects main effects
Fig 7. Drug Discrimination studies of nuciferine. (a,d) Nuciferine blocks the discriminative stimulus of DOI at doses that do not affect the rate of
responding. (b,e) Nuciferine does not block the discriminative stimulus of PCP at any dose tested. (e,f) Nuciferine substitutes for clozapine (solid circles) but
only at a dose that suppresses response rate (empty circles). Data are presented as % training-drug appropriate responding and response rate per second.
doi:10.1371/journal.pone.0150602.g007
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for the nuciferine [F(2,45) = 3.43, p<0.05] and PCP treatments [F(1,45) = 33.85, p<0.001], as well
as the nuciferine by PCP treatment interaction, were significant [F(2,45) = 3.31, p<0.05].
Decomposition of the interaction observed that PPI in the vehicle-vehicle, 5 mg/kg nuciferine-
vehicle, and 10 mg/kg nuciferine-vehicle groups were not differentiated from each other, but
that PPI in the PCP-vehicle group was suppressed relative to these controls (p<0.001). Despite
this fact, mice given nuciferine prior to PCP had higher PPI than the PCP-vehicle groups
(p<0.05) and the 10 mg/kg nuciferine-PCP group was not statistically different from the
respective control. Thus 10/mg/kg nuciferine rescued the PCP-disrupted PPI.
Analyses of responses from the DAT KOmice presented a different picture. A two-way
ANOVA for null activity observed significant genotype [F(1,102) = 12.410, p<0.005] and treat-
ment effects [F(4,102) = 18.516, p<0.001] and a significant genotype by treatment interaction
[F(4,102) = 3.956, p<0.01]. Bonferroni corrections demonstrated that null activity in DAT-KO
mice was higher than that in WT mice with clozapine (p<0.005) and 2.5 mg/kg nuciferine
Fig 8. Locomotor studies of nuciferine. (a) Nuciferine suppresses the PCP-induced hyperlocomotor
response. Data are presented as total distance travelled in 5-minute bins (left) and as cumulative distance
travelled between minute 45 and minute 60 (right). N = 18 mice; ^p<0.05, compared to PCP group. (b)
Nuciferine (3.0 mg/kg, 15 minute pretreatment) enhances the hyperlocomotor effect of amphetamine (3.0 mg/
kg) administration. N = 14 mice; * < 0.001 compared to Amphetamine group. Data are presented as above.
doi:10.1371/journal.pone.0150602.g008
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(p<0.01) (Fig 9D). Null activity in WT mice to clozapine and 5 mg/kg nuciferine were signifi-
cantly enhanced relative to the vehicle control (p<0.005), whereas null activity in DAT-KO
mice to clozapine and all doses of nuciferine were significantly augmented compared to vehicle
group (p<0.001). A two-way ANOVA for startle responses revealed significant main effects of
genotype [F(1,102) = 9.227, p<0.005] and treatment [F(4,102) = 28.673, p<0.001] (Fig 9E).
Regardless of genotype, clozapine-treated mice had higher startle responses than all other
groups (p<0.001). For PPI a RMANOVA found significant within-subject effects of prepulse
intensity [F(2,204) = 60.090, p<0.001] and a significant prepulse intensity by genotype interac-
tion [F(2,204) = 10.479, p<0.001]. Bonferroni tests demonstrated prepulse dependency in WT
animals where inhibition at each prepulse intensity was significantly different from each other
Fig 9. PPI responses to nuciferine in mousemodels of hypoglutamatergia and hyperdopaminergia.Nuciferine rescued PPI in the former, but not in
the latter model. (a-c) Null activity (a), startle activity (b), and PPI (c) for C57BL/6J mice treated with vehicle (Veh), 5 or 10 mg/kg nuciferine (Nuc), and/or
phencyclidine (PCP). (d-g) Null activity (d), startle activity (e), and PPI for wild-type (WT) (f) and dopamine transporter knockout (DAT-KO) mice (g) given
Veh, 2 mg/kg clozapine (CLZ) or 2.5–10 mg/kg Nuc. N = 8–17 mice/group in the C57BL/6J experiment; *p<0.05, compared to Veh/Nuc groups; +p<0.05,
compared to the Veh and PCP groups; †p<0.05, compared to all other groups. N = 9–17 mice/genotype/treatment in the DAT experiment; ^p<0.05, WT
versus KO within dose; #p<0.05, dose effect within genotype; &p<0.05, overall drug effect regardless of genotype.
doi:10.1371/journal.pone.0150602.g009
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(p<0.001) (Fig 9F). By contrast, in DAT-KO animals responses to the 12 dB prepulse were
higher than those to the 4 and 8 dB prepulses (p<0.005), which were not significantly distin-
guished from each other (Fig 9G). The between subjects test discerned significant genotype
[F(1,102) = 25.246, p<0.001] and treatment effects [F(4,102) = 4.238, p<0.005] and a significant
genotype by treatment interaction [F(4,102) = 3.288, p<0.05]. Bonferroni comparisons found
that PPI was significantly lower for DAT-KO thanWT mice in the groups given vehicle or any
dose of nuciferine (p<0.05). Clozapine significantly enhanced PPI in DAT-KO mice relative to
the vehicle and nuciferine treatments (p<0.05). Together, these data show that PPI is intact in
WT animals and it is not affected by either clozapine or nuciferine. By contrast, PPI is deficient
in DAT-KO mice and it was restored by clozapine but not by nuciferine.
3.8 Catalepsy
Nuciferine (10.0 mg/kg) did not produce catalepsy at any of the time-points examined
(Table 3).
4. Discussion
Here we present an in vitro and in vivo characterization of nuciferine, an alkaloid found in
Nelumbo nucifera and Nymphaue caerulea lotus plants. Our primary finding was that nucifer-
ine has a pharmacological profile similar but not identical to some antipsychotic drugs (espe-
cially aripiprazole) and that nuciferine performed as an antipsychotic-like drug in some animal
models predictive of antipsychotic drug-like actions. Here, we discuss these findings in the con-
text of antipsychotic pharmacology and animal models of antipsychotic efficacy.
4.1 Molecular characterization
The in silico prediction and in vitro characterization of nuciferine revealed a molecular affinity
profile containing receptors known to be modulated by established antipsychotic drugs. Within
the set of 13 receptors with<1 μM affinity, nuciferine showed greatest affinity at the serotoner-
gic receptors and overall it exhibited a molecular profile with multiple entities implicated in
clinical antipsychotic efficacy: 5-HT7 [29, 34, 40, 41], 5-HT6 [34], 5-HT2A [5], 5-HT1A [42],
5-HT1D [43], D2 [44], D1, D3, D4, D5 [45], α2B, and α2C [46]. The preponderance of low affinity
antagonism led us to test whether nuciferine forms colloidal aggregates. Parenthetically, colloi-
dal aggregation is a phenomenon that affects molecular pharmacological screening efforts and
has not been appreciated until relatively recently.[47] Compounds that form colloidal aggre-
gates can present unique and irrelevant behavior in vitro [48], and we avoided these confounds
by demonstrating that nuciferine does not form aggregates at concentrations up to 10 μM. Of
the non-GPCR targets that SEA predicted, SK channels have been shown to bind antipsychotic
compounds, [49] while VMAT2 is involved in monoaminergic neurotransmission and has
long been proposed as a target for antipsychotic drug activity.[50, 51] It is also interesting to
note that nuciferine does not bind to any muscarinic receptors. Muscarinic antagonists are pre-
scribed to prevent or treat extrapyramidal side effects of antipsychotics. [52–54] During the
Table 3. Cataleptic properties of nuciferine.
Post-injection timepoint (min) Vehicle Nuciferine10.0 mg/kg Haloperidol1.0 mg/kg
30 3 ± 2.08 s 2.3 ± 2.3 s 270 ± 30 s
60 2.67 ± 1.45 s 4.7 ± 2.6 s 300 ± 0 s
Nuciferine did not cause a latency to move in the inclined grid test compared to haloperidol at the doses and times tested.
doi:10.1371/journal.pone.0150602.t003
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course of our investigation, an independent group determined that nuciferine functions as a
5-HT2A antagonist [55], corroborating our findings at this receptor.
With respect to antipsychotic efficacy, the D2 receptor is a desired druggable target with all
approved antipsychotic drugs having potent interactions with this target.[30] In addition to D2
receptor affinity, however, it is also known that partial agonists have antipsychotic efficacy,
such as aripiprazole.[19, 31] Therefore, we examined the D2 functional properties of nuciferine
in comparison to aripiprazole and found that nuciferine exhibited a similar degree of partial
agonist activity compared to aripiprazole, suggesting that nuciferine could exhibit antipsy-
chotic drug-like properties, albeit with lower potency. The ability to block or antagonize DA-
stimulated D2 activity may be a better predictor of antipsychotic efficacy, especially in the case
of D2 partial agonists such as aripiprazole with low intrinsic efficacy in vitro,[56] which may
act as D2 antagonists in vivo. [57] To examine nuciferine’s antagonist activity, we chose to mea-
sure nuciferine’s ability to block DA-stimulated D2 activation using a Schild regression analy-
sis.[32] Results indicated that nuciferine can antagonize DA-stimulated cAMP inhibition with
a potency similar to clozapine. Clozapine, one of the most effective atypical antipsychotics, pos-
sesses lower affinity for the D2 receptor compared to typical antipsychotics, [5] and therefore it
is conceivable that just a moderate degree of D2 antagonism is needed for antipsychotic effi-
cacy, given that clozapine also possesses potent 5-HT2A antagonism, 5-HT1A partial agonist
activity, and 5-HT7 inverse agonism, which nuciferine also possesses. In summary, nuciferine
shares two properties of antipsychotic efficacy at the D2 receptor, namely partial agonist activ-
ity at the D2 receptor similar to aripiprazole, and antagonist activity with moderate affinity
comparable to clozapine.
There were notable discrepancies within our study across paradigms and compared to pre-
viously published findings. For instance, the SEA predicted one entity (dopamine D5 receptor)
that was not detected in the PDSP binding affinity assay but was detected in the functional assay.
The micromolar efficacy of nuciferine at the D5 receptor as measured via functional assays is con-
sistent with the low binding affinity, due to the fact that the antagonist radioligand [3H]SCH
23390 labels inactive states of the receptor. Additionally, the dopamine transporter (DAT) was
neither predicted using the SEA nor was it detected in the PDSP screen, yet it was determined
that nuciferine modulates the DAT in vitro using a functional assay, again suggesting that this
compound may be modulating the DAT at a site other than that occupied by the radioligand
[3H]WIN35428. Interestingly, our behavioral results with amphetamine in the open field also
support the notion that nuciferine interacts with DAT. It was previously reported that nuciferine
inhibits the hyperlocomotor effect of amphetamine [4], but in our study we observed an increase
in hyperlocomotor activity following nuciferine pretreatment. Our methods differed substantially
from those of Bhattacharya et al. [4] who used a considerably higher dose range (25–100 mg/kg)
of nuciferine, compared to our lower dose range (1–10 mg/kg across the study with 3.0 mg/kg
nuciferine in the amphetamine experiment). These discrepancies support the use of orthologous
assays in screening efforts to fully elucidate a chemical’s pharmacology.
The discovery of DAT modulation occurred serendipitously during the verification of the
SEA VMAT2 prediction due to the nature of the experimental system. In these experiments,
nuciferine caused an increase in uptake in cells expressing DAT but showed no effect in cells
expressing both DAT and VMAT2. Direct measurement of uptake in isolated vesicles failed to
detect direct modulation of VMAT2 by nuciferine. The difference between the results of the
DAT and DAT/VMAT2 cells suggests that nuciferine may be indirectly inhibiting vesicular
uptake in the HEK-DAT/VMAT2 cells, counteracting the increased DAT-mediated uptake.
This is likely an indirect modulation of VMAT2 because nuciferine did not directly affect
VMAT2 uptake in the isolated vesicle assay. However, further experiments are necessary to
determine the mechanism.
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4.2 Behavioral characterization
Since the initial studies of Macko and colleagues, our ability to assess antipsychotic efficacy in
animal models has improved. For example, deficits in sensorimotor gating observed in individ-
uals diagnosed with schizophrenia are modeled in rodents using the pre-pulse inhibition (PPI)
paradigm, in which the startle response to a stimulus is inhibited by a pulse of reduced magni-
tude preceding the acoustic startle stimulus. Deficits in PPI are observed in schizophrenia
patients and can be rescued by antipsychotic medications.[58] This deficit in PPI can be repro-
duced in animal models via administration of phencyclidine (PCP), a compound that produces
psychosis-like effects in humans, and the disrupted PPI can be rescued by antipsychotic com-
pounds.[59, 60] Notably, the rescue of PCP-induced disruption of PPI has been a hallmark of
preclinical antipsychotic drug discovery efforts as a predictive model of antipsychotic efficacy.
[61]
We thus set out to determine whether the identified molecular profile would translate into
antipsychotic drug-like actions as determined by several animal models commonly used to
study antipsychotic pharmacology. As mentioned previously, atypical antipsychotics exhibit
5-HT2A antagonist activity, and the potency with which antagonists attenuate the head-twitch
response is highly correlated with the antagonist's affinity for 5-HT2A receptors. [62, 63] The
ability of nuciferine to block the hallucinogen DOI-induced head-twitch response is consistent
with the in vitromeasurements of 5-HT2A antagonism and suggests activity in vivo via 5-HT2A
receptor blockade. Furthermore, the dissociative psychedelic PCP produces a psychomimetic
state in humans and the inhibition of PCP-induced behavioral effects is used as an animal
model for evaluating schizophrenia-like behaviors.[64, 65] Nuciferine blocked not only the
PCP-induced hyperlocomotor activity in the open field, but it also rescued PCP-disrupted PPI
without direct antagonism of the NMDA PCP binding site. Despite clozapine rescuing PPI in
DAT-KO mice, nuciferine failed to normalize PPI in the DAT-KO genetic mouse model of
hyperdopaminergia or in the pharmacological model using amphetamine (data not shown). At
this time, the molecular basis of the distinctions between the differential responses in the hypo-
glutamateric and hyperdopaminergic models is obscure. To our knowledge, this is the first
report of nuciferine’s efficacy in these animal models and our results indicate that this com-
pound has greater efficacy in hypoglutamateric than in hyperdopaminergic animal models
The drug discrimination paradigm utilizes the interoceptive properties of drugs as a means
to study their pharmacology. We used this paradigm to assess nuciferine’s pharmacology due
to its unique ability to measure a systems-level pharmacological effect (as would be caused by a
compound with high polypharmacology) at a whole organism level of analysis and due to its
use in drug discovery efforts in the past.[66, 67] Nuciferine’s antagonism of the DOI-induced
discriminative stimulus is consistent with its capacity to also antagonize DOI-induced head
twitches and this result further validates the 5-HT2A antagonism observed in vitro. Interest-
ingly, nuciferine did not block the PCP-induced discriminative stimulus. It should be empha-
sized that other investigators have reported that antipsychotics do not antagonize the
discriminative stimulus of PCP. [68] Finally, nuciferine fully substituted for clozapine at the
highest dose tested (10.0 mg/kg), indicating that nuciferine produced an interoceptive state
similar to that of clozapine. Previous studies in C57BL/6 mice have shown that 5-HT2A seroto-
nergic and α1-adrenoceptor antagonism mediate clozapine’s discriminative stimulus. [69] It
should be noted that the 10.0 mg/kg dose of nuciferine that substituted for clozapine also pro-
duced significant rate suppression compared to vehicle control rates; however, previous studies
have shown that the doses of antipsychotics that produce full substitution for clozapine are
often accompanied by significant rate suppression (in both rats [70, 71] and mice[72, 73]).
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4.3 Conclusion
In conclusion, we have comprehensively elucidated a complex pharmacological profile for
nuciferine, one of the main alkaloids present in Nelumbo nucifera. The molecular profile of
nuciferine was similar but not identical to the profiles of several approved antipsychotic drugs
suggesting that nuciferine has atypical antipsychotic-like actions.
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